25 results about "Surface Glycoproteins" patented technology

The present invention provides a vaccine composition comprising a therapeutically effective amount of whole influenza virus, split influenza virus, virus like particle (VLP) or a combination thereof wherein one or more surface viral glycoproteins of the whole influenza virus, split influenza virus or VLP is partially glycosylated; and wherein the whole influenza virus and the split influenza virus has been attenuated or inactivated. The present invention also provides a method of preparation of the vaccine comprising the steps of injecting working virus seed with an inhibitor of the mannosidase into embryonated chicken egg to inoculate the embryonated chicken egg; incubating the inoculated embryonated chicken egg to propagate the working vims; harvesting allantonic fluids from the inoculated embryonated chicken egg; concentrating and clarifying the harvested allantonic fluids; purifying the concentrated and clarified allantonic fluids using sucrose density centrifugation; applying deglycosylation enzyme to the purified allantonic fluid to partially glycosylate viral surface glycoprotein of the propagated vims within the purified allantonic fluid; removing deglycosylation enzyme from whole vims with partially glycosylated viral surface glycoprotein; and inactivating the vims. The present invention further provides a method of treatment for prevention of influenza infection comprising the step of administering any embodiment of the vaccine of the present invention to a subject.

Antigen binding proteins of the invention bind to Human Immunodeficiency Virus (HIV) envelope protein and are useful in treating and preventing HIV infection. In particular, the antigen binding proteins bind to two different epitopes on HIV envelope surface glycoprotein 120 (gp120): the V3 loop region and the CD4 binding site.

This disclosure relates to structurally-stabilized (e.g., stapled, e.g., hydrocarbon stapled) Ebolavirus peptides and variants thereof, and structurally-stabilized (e.g., stapled, e.g., hydrocarbon stapled) Ebolavirus peptides and variants thereof, conjugated with polyethylene glycol (PEG) and / or cholesterol (or a variant thereof, e.g., thiocholesterol), e.g., a generated PEG(n)-cholesterol or PEG(n)-thiocholesterol derivatization to further optimize activity, and methods for using such structurally-stabilized peptide conjugates in the prevention and treatment of an Ebolavirus infection or disease in a subject (e.g., human, non-human primate, or fruit bat). The disclosure also relates to methods of using such structurally-stabilized peptides and conjugates in the prevention and treatment of a Marburg virus infection, a Bombali ebolavirus infection, or a Mengla dianlovirus infection in a subject.

Antigen binding proteins of the invention bind to Human Immunodeficiency Virus (HIV) envelope protein and are useful in treating and preventing HIV infection. In particular, the antigen binding proteins bind to two different epitopes on HIV envelope surface glycoprotein 120 (gp120): the V3 loop region and the CD4 binding site.

The present disclosure provides compositions and methods for manufacturing and obtaining a live attenuated Influenza vaccine (LAIV) composition that can be delivered intranasally to provide protection against influenza virus infection. Said LAIV strains are based on cold adapted, temperature sensitive and attenuated phenotypes of master donor viruses (MDVs) containing the surface glycoprotein genes of the wild type pandemic or seasonal influenza strains. Also, said LAIV strains are further adapted to grow in MDCK cells (Madin Darby canine kidney cells). The use of eggs is avoided in large scale vaccine manufacturing. The purification process is devoid of chromatography steps. The said LAIV composition includes one or more live attenuated influenza vaccine virus and is devoid of polymers and surfactants.

Lassa fever is a zoonotic viral hemorrhagic disease caused by Lassa virus (LASV), endemic in multiple west African countries where the multimammate rat is a main virus reservoir. The broad geographic range of the rodent host places a large population at risk of serious illness. LASV is also a bioterrorism threat. A LASV vaccine is an unmet need. Applicants advance a vaccine based on a live vesicular stomatitis virus vector for immunizing against the LASV surface glycoprotein. Preclinical evaluation exhibited high efficacy in cynomolgus macaques. The animals developed serum antibodies that could mediate antiviral effector functions including direct neutralization of virus infectivity. This vaccine candidate elicited robust protective immunity in cynomolgus macaques that prevented development of detectable viremia and disease for at least 1 year after vaccination. These protective immune response features provide valuable data for comparison to an ongoing phase 1 clinical trial and planned phase 2b / 3 clinical trials.

The invention relates to the technical field of immune globulins, in particular to a rabbit monoclonal antibody for resisting T cell surface glycoprotein CD1a or an antigen binding fragment of the rabbit monoclonal antibody, a preparation method and application of the rabbit monoclonal antibody. The rabbit monoclonal antibody for resisting the T cell surface glycoprotein CD1a protein is characterized in that amino acid sequences of LCDR1, LCDR2 and LCDR3 of VL of the rabbit monoclonal antibody for resisting the T cell surface glycoprotein CD1a protein are respectively shown as SEQ ID NO.4-6; the amino acid sequences of the HCDR1, the HCDR2 and the HCDR3 of the VH are as shown in SEQ ID NO.8 to SEQ ID NO.10. The invention further provides an immunohistochemical detection kit containing the anti-human CD1a protein rabbit monoclonal antibody and application of the antibody or the kit in immunohistochemical detection, and the anti-human CD1a protein rabbit monoclonal antibody has high specificity and sensitivity, can be applied to marking of CD1a protein in tissue cells, and can be used for immunohistochemical detection. The specificity and the reliability of immunodetection of the CD1a protein are obviously improved.

Described are structural identifications of the F and G proteins of a large variety Henipaviruses and their use in creating immunogens useful for vaccine compositions, and in prevention and treatment of Paramyxovirus and Henipavirus infections in a mammal. Also described are methods for screening viral fusion proteins for capability to transition from a pre-fusion to a post-fusion conformation. A monoclonal antibody specific for LayV-F is also provided.

The present disclosure relates to structurally stable (e.g., stapled, e.g., hydrocarbon stapled) respiratory syncytial virus (RSV) peptides and variants thereof, and structurally stable (e.g., stapled, e.g., hydrocarbon stapled) RSV peptides conjugated to polyethylene glycol (PEG) and / or cholesterol (or variants thereof, e.g., mercaptocholesterol), e.g., PEG (n)-cholesterol or PEG (n)-mercaptocholesterol derivatizations, e.g., polyethylene glycol (n)-cholesterol, e.g., polyethylene glycol (n)-cholesterol, e.g., polyethylene glycol (n)-cholesterol, e.g., polyethylene glycol (n)-cholesterol, e.g., polyethylene glycol (n)-cholesterol. And methods of using such structurally stable peptides and conjugates to prevent and treat RSV infection in subjects (e.g., humans).

The antigen-binding proteins of the present invention bind to human immunodeficiency virus (HIV) envelope proteins and are useful in the treatment and prevention of HIV infection. In particular, the antigen-binding proteins bind to two distinct epitopes on the HIV envelope surface glycoprotein 120 (gp120): the V3 loop region and the CD4 binding site.

The present invention relates to recombinant Modified Vaccina Virus Ankara (MVA) encoding Epstein-Barr virus (EBV) antigens, wherein surface glycoprotein 350 (EBV gp350) and glycoprotein gH (EBV gH) are fused to subunits of self-assembling multimeric protein particle PdhC (acetyltransferase of pyruvate dehydrogenase (PDH) complex) or DPS (DNA binding protein from starved cells).

Systems and methods are described herein enabling the profiling of local microenvironments across the sialylated proteome via proximity labeling. In one aspect, conjugates are described herein having composition and electronic structure for generating reactive labeling intermediates in microenvironments of sialylated cell-surface glycoproteins. In some embodiments, a conjugate comprises a transition metal catalyst coupled to a cell surface glycoprotein. As described further herein, the transition metal catalyst can be coupled to the glycoprotein via a derivatized sialic acid linker.

This disclosure relates to structurally-stabilized (e.g., stapled, e.g., hydrocarbon stapled) respiratory syncytial virus (RSV) peptides and variants thereof, and structurally-stabilized (e.g., stapled, e.g., hydrocarbon stapled) RSV peptides and variants thereof, conjugated with polyethylene glycol (PEG) and / or cholesterol (or a variant thereof, e.g., thiocholesterol), e.g., a PEG(n)-cholesterol or PEG(n)-thiocholesterol derivatization, and methods for using such structurally-stabilized peptides and conjugates in the prevention and treatment of an RSV infection in a subject (e.g., human).

The antigen binding proteins of the invention bind to human immunodeficiency virus (HIV) envelope proteins and are useful in the treatment and prevention of HIV infection. In particular, the antigen binding protein binds to two different epitopes (V3 loop region and CD4 binding site) on HIV envelope surface glycoprotein 120 (gp120).

The invention discloses a VSV vector, prepared recombinant VSV virus particles can express EBV gp42 protein in host cells and can cause remarkable specific antibody reaction aiming at EBV surface glycoprotein gp42, a monovalent gp42 vaccine can initiate strong and lasting humoral immunity, and it is indicated that the VSV is an appropriate vaccine vector of gp42. The specific antibody generated by the VSV-based gp42 vaccine can inhibit EBV infection epithelial cells and B lymphocytes, which indicates that the VSV-based EBV vaccine has the potential for preventing and controlling EBV infection and related neoplastic and non-neoplastic diseases of people.

The invention is based on a platform for vaccination and / or antibody generation. The invention is based on the display of small molecular immunogenic compounds on the coat of variant surface glycoproteins (VSG) on trypanosomes which results in a highly effective immune response when used as a vaccine or in immunization for antibody production. The herein disclosed antigenic particles are applicable for producing antibodies or can be directly used as vaccines for the treatment of various medical conditions. Most preferably the invention relates to the VSG based vaccines specific for dependency causing substances for the treatment of addiction or avoidance of adverse events during drug abuse. Other applications include methods and uses involving the disclosed compounds and compositions for a treatment or prevention of cancer, infectious disease, contagious neurodegenerative diseases, non-communicable disorders (e.g. certain neurodegenerative diseases, allergies) and any condition or industrial use for which an immune response from vaccination or antibody use would be desirable.

This disclosure relates to structurally stabilized (e.g., stapled, e.g., hydrocarbon-stapled) respiratory syncytial virus (RSV) peptides and their variants, and structurally stabilized (e.g., stapled, e.g., hydrocarbon-stapled) RSV peptides and their variants conjugated with polyethylene glycol (PEG) and / or cholesterol (or its variants, e.g., thiocholesterol), e.g., PEG(n)-cholesterol or PEG(n)-thiocholesterol derivatization, and to methods for using such structurally stabilized peptides and conjugates in the prevention and treatment of RSV infection in subjects (e.g., humans).

Lassa fever is a zoonotic viral hemorrhagic disease caused by Lassa virus (LASV), endemic in multiple west African countries where the multimammate rat is a main virus reservoir. The broad geographic range of the rodent host places a large population at risk of serious illness. LASV is also a bioterrorism threat. A LASV vaccine is an unmet need. Applicants advance a vaccine based on a live vesicular stomatitis virus vector for immunizing against the LASV surface glycoprotein. Preclinical evaluation exhibited high efficacy in cynomolgus macaques. The animals developed serum antibodies that could mediate antiviral effector functions including direct neutralization of virus infectivity. This vaccine candidate elicited robust protective immunity in cynomolgus macaques that prevented development of detectable viremia and disease for at least 1 year after vaccination. These protective immune response features provide valuable data for comparison to an ongoing phase 1 clinical trial and planned phase 2b / 3 clinical trials.

This invention discloses a method for diagnosing prostate cancer using exosome surface proteomics, aiming to address the technical problems of insufficient specificity in existing prostate-specific antigen (PSA) detection and the inability of conventional exosome analysis techniques to simultaneously achieve source specificity and proteome coverage. The method includes: collecting and preprocessing biological fluid samples; using a dual-marker orthogonal barcoding system composed of DNA aptamer probes targeting CD63 protein and prostate-specific membrane antigen, respectively, to specifically capture and enrich prostate cancer-derived exosomes; selectively labeling their surface glycoproteins, followed by cleavage and enzymatic digestion to enrich surface glycoprotein peptides; and finally, inputting the data into a diagnostic model trained based on machine learning to output diagnostic results. This invention, through the organic combination of source-specific capture and panoramic surface proteome analysis, significantly improves the specificity and sensitivity of diagnosis, providing an efficient solution for non-invasive and accurate diagnosis and invasiveness assessment of prostate cancer.

The present disclosure provides compositions and methods for manufacturing and obtaining live attenuated influenza vaccine (LAIV) compositions that can be delivered intranasally to provide protection against influenza virus infection. The LAIV strains are based on the cold-adapted, temperature-sensitive, and attenuated phenotypes of a master donor virus (MDV) comprising the surface glycoprotein genes of wild-type pandemic or seasonal influenza strains. Moreover, the LAIV strains are further adapted to grow in MDCK cells (Madin-Darby canine kidney cells). Eggs are avoided in large-scale vaccine production. The purification process has no chromatographic steps. The LAIV composition comprises one or more live attenuated influenza vaccine viruses and is free of polymers and surfactants.

The invention discloses a multi-epitope peptide of Ebola virus, a vaccine as well as a preparation method and application of the multi-epitope peptide and the vaccine, and belongs to the technical field of biological medicines. The multi-epitope peptide is derived from surface glycoprotein (Glycoprotein, GP) of Zaire type Ebola virus and Sudan type Ebola virus, and the epitope peptide is conserved in the two types of Ebola viruses. In addition, the multi-epitope peptide is both a T cell epitope and a B cell epitope. An epitope peptide and a nano delivery carrier are connected through a linker to prepare a vaccine, the vaccine comprises the multi-epitope peptide or a combination thereof, a free KFE8 self-assembly peptide and a PADRE-KFE8 fusion peptide, and a nano fiber structure is formed through self-assembly of the multi-epitope peptide or the combination thereof, the free KFE8 self-assembly peptide and the PADRE-KFE8 fusion peptide. The preparation method comprises the following steps: dissolving the components in a buffer solution according to a specific molar ratio, and incubating to enable the components to be self-assembled to form nanofibers. The multi-epitope peptide can be used for preparing a vaccine for preventing Ebola virus infection, and the vaccine can induce humoral immunity and cellular immunity at the same time, and has broad-spectrum protection potential for Zaire type and Sudan type Ebola viruses at the same time.

The present disclosure provides compositions and methods for manufacturing and obtaining a live attenuated Influenza vaccine (LAIV) composition that can be delivered intranasally to provide protection against influenza virus infection. Said LAIV strains are based on cold adapted, temperature sensitive and attenuated phenotypes of master donor viruses (MDVs) containing the surface glycoprotein genes of the wild type pandemic or seasonal influenza strains. Also, said LAIV strains are further adapted to grow in MDCK cells (Madin Darby canine kidney cells). The use of eggs is avoided in large scale vaccine manufacturing. The purification process is devoid of chromatography steps. The said LAIV composition includes one or more live attenuated influenza vaccine virus and is devoid of polymers and surfactants.

The application discloses a recombinant human CD8 alpha protein and a preparation method and application thereof, and belongs to the technical field of biotechnology. Two signal peptides and three labels are designed for a human T cell surface glycoprotein CD8 alpha, and are combined for use. It is found that under the condition that the signal peptides B and C-human Fc label exist, efficient secretion expression of the target protein can be realized, the recombinant human CD8 alpha protein is successfully obtained through affinity purification, the SDS-PAGE electrophoresis strip of the target protein is clear and single, and the yield is high. The recombinant human CD8 alpha protein antigen prepared through the preparation method (production process) has good immunogenicity, and animals immunized with the recombinant human CD8 alpha protein antigen can generate specific polyclonal antibodies. The preparation method (production process) can be effectively applied to large-scale production of the recombinant human CD8 alpha protein antigen, and the recombinant human CD8 alpha protein antigen is used as an immunogen for immunization, antibody preparation and production, and is further used for diagnosis of a disease marker CD8 alpha of familial CD8 deficiency.

The invention is based on a platform for vaccination and / or antibody generation. The invention is based on the display of small molecular immunogenic compounds on the coat of variant surface glycoproteins (VSG) on trypanosomes which results in a highly effective immune response when used as a vaccine or in immunization for antibody production. The herein disclosed antigenic particles are applicable for producing antibodies or can be directly used as vaccines for the treatment of various medical conditions. Most preferably the invention relates to the VSG based vaccines specific for dependency causing substances for the treatment of addiction or avoidance of adverse events during drug abuse. Other applications include methods and uses involving the disclosed compounds and compositions for a treatment or prevention of cancer, infectious disease, contagious neurodegenerative diseases, non-communicable disorders (e.g. certain neurodegenerative diseases, allergies) and any condition or industrial use for which an immune response from vaccination or antibody use would be desirable.

The present invention relates to a protein derived from the extracellular domain of the surface protein ISG65 (invariant surface glycoprotein 65 (Tbg.972.2.1600) of the human parasite Trypanosoma brucei gambiense. The ISG65-derived protein is useful in the treatment of complement dysregulation diseases. In one aspect, the present invention provides a novel thermostable mutant of ISG65.